Ketamine for the treatment of addiction: Evidence and potential mechanisms.
Reads0
Chats0
TLDR
Preclinical and clinical research into ketamine's ability to treat addiction shows great promise as a treatment for various addictions, but well‐controlled research is urgently needed.About:
This article is published in Neuropharmacology.The article was published on 2018-01-12 and is currently open access. It has received 87 citations till now. The article focuses on the topics: Addiction.read more
Citations
More filters
Journal ArticleDOI
When Not Enough Is Too Much: The Role of Insufficient Glucocorticoid Signaling in the Pathophysiology of Stress-Related Disorders
TL;DR: Neuroendocrine data provide evidence of insufficient glucocorticoid signaling in stress-related neuropsychiatric disorders, including posttraumatic stress disorder and major depression, which are associated with immune system activation/inflammation, high SNS tone, and CRH hypersecretion.
Journal ArticleDOI
The Neuroscience of Drug Reward and Addiction.
TL;DR: Treatment interventions intended to reverse neuroadaptations that result in an impaired prefrontal top-down self-regulation that favors compulsive drug-taking against the backdrop of negative emotionality and an enhanced interoceptive awareness of "drug hunger" show promise as therapeutic approaches for addiction.
Journal ArticleDOI
The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
Chadi G. Abdallah,Chadi G. Abdallah,Gerard Sanacora,Ronald S. Duman,John H. Krystal,John H. Krystal +5 more
TL;DR: The current perspective paper summarizes the understanding of the neurobiology of depression, and the mechanisms of action of ketamine and other RAADs, and summarize the clinical efficacy findings of putative RAads, present relevant human biomarker findings, and discuss current challenges and future directions.
Journal ArticleDOI
The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder
Chadi G. Abdallah,Lynnette A. Averill,Teddy J. Akiki,Mohsin Raza,Christopher L. Averill,Hassaan Gomaa,Archana Adikey,John H. Krystal +7 more
TL;DR: This work summarizes the standard and experimental pharmacotherapeutic options for PTSD, and discusses their putative mechanism of action and clinical efficacy, and proposes a dual pathology model of stress-related synaptic loss arising from amino acid-based pathology and stress- related synaptic gain related to monoamine- based pathology.
A comparison of self-reported symptoms and DSM-III-R criteria for cocaine withdrawal
TL;DR: The frequencies of 15 self-reported symptoms of cocaine withdrawal were compared in 75 subjects to the symptoms listed as criteria by DSM-III and DSM-R for either amphetamine or cocaine withdrawal, finding that these criteria may be too narrowly defined for treatment purposes.
References
More filters
Journal ArticleDOI
Diagnostic and Statistical Manual of Mental Disorders
Vijay A. Mittal,Elaine F. Walker +1 more
TL;DR: An issue concerning the criteria for tic disorders is highlighted, and how this might affect classification of dyskinesias in psychotic spectrum disorders.
Journal ArticleDOI
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).
Ronald C. Kessler,Patricia A. Berglund,Olga Demler,Robert Jin,Doreen S. Koretz,Kathleen R. Merikangas,A. John Rush,Ellen E. Walters,Philip S. Wang +8 more
TL;DR: Notably, major depressive disorder is a common disorder, widely distributed in the population, and usually associated with substantial symptom severity and role impairment, and while the recent increase in treatment is encouraging, inadequate treatment is a serious concern.
Journal ArticleDOI
Neurocircuitry of Addiction
George F. Koob,Nora D. Volkow +1 more
TL;DR: The delineation of the neurocircuitry of the evolving stages of the addiction syndrome forms a heuristic basis for the search for the molecular, genetic, and neuropharmacological neuroadaptations that are key to vulnerability for developing and maintaining addiction.
Journal ArticleDOI
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores-Wilson,Melanie M. Biggs,Goundappa K. Balasubramani,Maurizio Fava +13 more
TL;DR: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Related Papers (5)
Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research
Evgeny Krupitsky,A. Y. Grinenko +1 more
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Panos Zanos,Ruin Moaddel,Patrick J. Morris,Polymnia Georgiou,Jonathan Fischell,Greg I. Elmer,Manickavasagom Alkondon,Peixiong Yuan,Heather J. Pribut,Nagendra Singh,Katina Sourou Sylvestre Dossou,Yuhong Fang,Xi Ping Huang,Cheryl L. Mayo,Irving W. Wainer,Edson X. Albuquerque,Scott M. Thompson,Craig J. Thomas,Carlos A. Zarate,Todd D. Gould +19 more